Background and objective Pirfenidone is an oral antifibrotic agent that is approved in several
countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a …

Summary Background In this retrospective Italian study, which involved all major national
interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease …

Objective We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and
clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic …

Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective
therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial …

Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of …

This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease
progression and the effects of pirfenidone in patients stratified by more preserved versus …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …

Background RECAP is an open-label extension study evaluating pirfenidone in patients with
idiopathic pulmonary fibrosis (IPF) who completed the Phase 3 CAPACITY program …

Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …